Study protocol for a multicentre randomised controlled trial: Safety, Tolerability, efficacy and quality of life Of a human recombinant alkaline Phosphatase in patients with sepsis-associated Acute Kidney Injury (STOP-AKI)

INTRODUCTION: Acute kidney injury (AKI) occurs in 55–60% of critically ill patients, and sepsis is the most common underlying cause. No pharmacological treatment options are licensed to treat sepsis-associated AKI (SA-AKI); only supportive renal replacement therapy (RRT) is available. One of the lim...

Descripción completa

Detalles Bibliográficos
Autores principales: Peters, Esther, Mehta, Ravindra L, Murray, Patrick T, Hummel, Jürgen, Joannidis, Michael, Kellum, John A, Arend, Jacques, Pickkers, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Intensive Care
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5051490/
https://www.ncbi.nlm.nih.gov/pubmed/27678541
http://dx.doi.org/10.1136/bmjopen-2016-012371

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5051490/
https://www.ncbi.nlm.nih.gov/pubmed/27678541
http://dx.doi.org/10.1136/bmjopen-2016-012371

Ejemplares similares